Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Synaffix
Synaffix
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Research & Development
Innovent Biologics and Synaffix expand ADC collaboration
New deal builds on encouraging preliminary clinical data from the Phase I study of the first antibody-drug conjugate (ADC) developed under the agreement signed in June 2021
Drug Delivery
Lonza to acquire Synaffix and strengthen ADCs offering
The companies will continue to expand their "Centre of Excellence" for bioconjugate technology development, with a focus on out-licensing bioconjugates technologies
Regulatory
Synaffix expands licensing agreement with MacroGenics
The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion
Distribution
Synaffix announces licensing agreement with CKD Pharm
Under the terms of the agreement, Synaffix has received an upfront payment and is eligible to receive further milestone payments
Drug Delivery
Synaffix enters ADCs agreement with Amgen
Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments
Digital
Synaffix wins ‘Best ADC Platform Technology’ at World ADC Awards
This marks the second time that Synaffix’s ADC platform technology has been acknowledged as industry leading
Research & Development
Synaffix strikes ADC deal with MacroGenics
Under the agreement, Synaffix will be eligible to receive up to $586m in payments
Subscribe now